Summary
Amgen Inc. has announced a definitive agreement to acquire Abgenix, Inc. through a merger valued at $22.50 per share in cash. This strategic move, detailed in an 8-K filing dated December 14, 2005, signifies Amgen's intent to expand its capabilities and product pipeline through a significant acquisition. The transaction is subject to customary closing conditions, including shareholder approval and regulatory clearance. This acquisition is expected to enhance Amgen's position in the biotechnology sector. Investors should monitor the progress of regulatory approvals and shareholder votes, as these will be critical determinants for the completion of the merger. The deal's structure, involving an all-cash offer, indicates a straightforward acquisition aimed at immediate integration.
Key Highlights
- 1Amgen Inc. entered into a definitive Agreement and Plan of Merger with Abgenix, Inc. on December 14, 2005.
- 2The proposed merger will acquire Abgenix for $22.50 per share in cash.
- 3A subsidiary, Athletics Merger Sub, Inc., will be merged with Abgenix.
- 4Options and stock purchase rights of Abgenix will be handled according to the terms of the merger agreement, with some becoming fully vested and others converted into rights for Amgen stock.
- 5The Boards of Directors of both companies have unanimously approved the merger agreement.
- 6Customary conditions for closing include Abgenix shareholder approval and regulatory approvals, such as Hart-Scott-Rodino clearance.
- 7The agreement outlines termination clauses, including a potential $75 million termination fee payable by Abgenix under certain circumstances.